Startups
Apellis Pharmaceuticals
Develops and commercialises medicines that inhibit the complement immune system, including treatments for geographic atrophy and paroxysmal nocturnal haemoglobinuria. Biogen completed its acquisition of Apellis on 14 May 2026.
Team
A. Sinclair DunlopDirector (reported in the annual report published in 2025) |
Alec MachielsDirector (reported in the annual report published in 2025) |
Caroline BaumalChief Medical Officer (reported in the annual report published in 2025) |
Cedric FrancoisCo-Founder, President and CEO (reported in the annual report published in 2025) |
Craig WheelerDirector (reported in the annual report published in 2025) |
David WatsonGeneral Counsel and Secretary (reported in the annual report published in 2025) |
 Gerald ChanDirector (reported in the annual report published in 2025) |
Jim ChopasVice President and Chief Accounting Officer (reported in the annual report published in 2025) |
Keli WalbertDirector (reported in the annual report published in 2025) |
Mark DeLongChief Business and Strategy Officer (reported in the annual report published in 2025) |
Nur NicholsonChief Technical Operations Officer (reported in the annual report published in 2025) |
Pascal DeschateletsChief Scientific Officer (reported in the annual report published in 2025) |
Paul FonteyneDirector (reported in the annual report published in 2025) |
Stephanie Monaghan O’BrienDirector (reported in the annual report published in 2025) |
Timothy SullivanChief Financial Officer and Treasurer (reported in the annual report published in 2025) |